Towards a dynamic approach of experimental parkinsonism

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 22, Issue 8, 1998, Pages 1317-1329

  Bezard, Erwan ^a,b   Boraud, Thomas ^a   Imbert, Christelle ^a   Dovero, Sandra ^a   Bioulac, Bernard ^a   Gross, Christian E ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Monkey; Mouse; MPTP; Slow evolution of disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BENSERAZIDE PLUS LEVODOPA; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MACACA; MESENCEPHALON; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PARKINSONISM; SUBSTANTIA NIGRA;

EID: 0032213119     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00072-4     Document Type: Article

References (46)

1. AGID, Y. (1991) Parkinson's disease: pathophysiology. Lancet 337: 1321-1323
2. ASKARI, S., MIKHAIL, E. W., SMITH, W. K., WOODWARD, D. J., and GERMAN, D. C. (1986) Midbrain dopamine neurons in man: effects of Parkinson's disease on the regional distribution of cells. Soc. Neurosci. Abstr., Washington 12: 83
3. BANKIEWICZ, K. S., OLDFIELD, E. H., CHIUEH, C. C., DOPPAMN, J. L., JACOBOWITZ, D. M., and KOPIN, I. J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of MPTP. Life Sci. 39: 7-16
4. BENAZZOUZ, A., BORAUD, T., DUBEDAT, P., BOIREAU, A., STUTZMANN, J. M., and GROSS, C. (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: A preliminary study. Eur. J. Pharmacol. 284: 299-307
5. BENAZZOUZ, A., GROSS, C., and BIOULAC, B. (1992) MPTP-induced hemiparkinsonism in monkeys: behavioral, mechanographic, electromyographic and immunohistochemical studies. Exp. Brain Res. 90: 116-120
6. BEZARD, E., BIOULAC, B., AND GROSS, C. (1998a) Glutamatergic compensatory mechanisms in experimental parkinsonism. Prog. Neuro-Psychopharmacol. 22: 609-623
7. BEZARD, E., BORAUD, T., BIOULAC, B., AND GROSS, C. (1997a) Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 81: 399-404
8. BEZARD, E., BORAUD, T., BIOULAC, B., AND GROSS, C. (1998b) Evolution of the multiunit activity of basal ganglia in the course of a dynamic experimental parkinsonism. (submitted)
9. BEZARD, E., BORAUD, T., BIOULAC, B., AND GROSS, C. E. (1997b) Presymptomatic revelation of experimental parkinsonism. Neuroreport 8: 435-438
10. BEZARD, E., DOVERO, S., BIOULAC, B., AND GROSS, C. (1997c) Effect of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp. Neurol. 148: 288-292
11. BEZARD, E., IMBERT, C., DELOIRE, X., BIOULAC, B., AND GROSS, C. (1997d) A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res. 766: 107-112
12. BRAAK, H., BRAAK, E., YILMAZER, D., VOS, R. A. I. D., JANSEN, E. N. H., AND BOHL, J. (1996) Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J. Neural Transm. 103: 455-490
13. BURNS, R. S., CHIUEH, C. C., MARKEY, S. P., EBERT, M. H., JACOBOWITZ, D. J., AND KOPIN, I. J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. P. Natl. Acad. Sci. USA 80: 4546-4550
14. CHIUEH, C. C., MARKEY, S. D., BURNS, R. S., JOHANNESSEN, J. N., JACOBOWITZ, D. M., AND KOPIN, I. J. (1984) Neurochemical and behavioral effects of MPTP in rat, guinea pig and monkey. Psychopharmacol. Bull. 20: 548-553
15. CLOUGH, C. G. (1991) Parkinson's disease: management. Lancet 337: 1324-1327
16. DAVIS, G. C., WILLIAMS, A. C., MARKEY, S. P., EBERT, M. H., CAINE, E. D., REICHERT, C. M., AND KOPIN, I. J. (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1: 249-254
17. DOUDET, D., GROSS, C., LEBRUN-GRANDIE, P., AND BIOULAC, B. (1985) MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study. Brain Res. 335: 194-199
18. EHRINGER, H., AND HORNYKIEWICZ, O. (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38: 1236-1239
19. FEARNLEY, J. M., AND LEES, A. J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114: 2283-2301
20. GERLACH, M., AND RIEDERER, P. (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103: 987-1041
21. GERLACH, M., RIEDERER, P., PRZUNTEK, H., AND YOUDIM, M. B. H. (1991) MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208: 273-286
22. HASSLER, R. (1938) Zur Pathologie der Paralysis Agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48: 387-476
23. HEIKKILA, R. E., STEBER, B. A., MANZINO, L., AND SONSALLA, P. K. (1989) Some features of the nigrostriatal neurotoxin MPTP in the mouse. Mol. Chem. Neuropathol. 10: 171-183
24. HIRSCH, E. C. (1994) Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol. Neurobiol. 9: 135-142
25. HIRSCH, E. C., MOUATT, A., THOMASSET, M., JAVOY-AGID, F., AGID, Y., AND GRAYBIEL, A. M. (1992) Expression of calbindin D28K-like immunoreactivity in catecholaminergic cell groups of the human midbrain : normal distribution and distribution in Parkinson's disease. Neurodegeneration 1: 83-93
26. HOEHN, H. M., AND YAHR, M. D. (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442
27. JACKSON-LEWIS, V., JAKOWEC, M., BURKE, R. E., AND PRZEDBORSKI, S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257-269
28. JAVOY-AGID, F., TAQUET, H., PLOSKA, A., CHERIF-ZAHAR, C., RUBERG, M., AND AGID, Y. (1981) Distribution of catecholamines in the ventral mesencephalon of human brain, with special reference to Parkinson's disease. J. Neurochem. 36: 2101-2105
29. KOLLER, W. C. (1992) When does Parkinson's disease begin? Neurology 42: 27-31
30. KOLLER, W. C., LANGSTON, J. W., HUBBLE, J. P., IRWIN, I., ZACK, M., GOLBE, L., FORNO, L., ELLENBERG, J., KURLAND, L., AND RUTTENBERGER, A. J. (1991) Does a long preclinical period occur in Parkinson's disease? Neurology 41: 8-13
31. LANGSTON, J. W., BALLARD, P. A., TETRUD, J. W., AND IRWIN, I. (1983) Chronic parkinsonism in human due to a product of meperidine analog synthesis. Science 219: 979-980
32. LANGSTON, J. W., FORNO, L. S., REBERT, C. S., AND IRWIN, I. (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl 1-1,2,3,6, tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292: 390-394
33. LANGSTON, J. W., WIDNER, H., GOETZ, C. G., BROOKS, D., FAHN, S., FREEMAN, T., AND WATTS, R. (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov. Disord. 7: 2-13
34. MCGEER, P. L., ITAGAKI, S., AKIYAMA, H., AND MCGEER, E. G. (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24: 574-576
35. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 119: 585-591
36. NELSON, E. L., LIANG, C. L., SINTON, C. M., AND GERMAN, D. C. (1996) Midbrain dopaminergic neurons in the mouse: computer-assisted mapping. J. Comp. Neurol. 369: 361-371
37. PARE, D., DOSSI, R. C., AND STERIADE, M. (1990) Neuronal basis of the parkinsonian resting tremor: a hypothesis and its implication for treatment. Neuroscience 35: 217-226
38. SCHNEIDER, J. S., AND KOVELOWSKI, C. J. (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. 519: 122-128
39. SCHNEIDER, J. S., YUWILER, A., AND MARKHAM, C. H. (1987) Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Brain Res. 411: 144-150
40. SCHULTZ, W., STUDER, A., JONSSON, G., SUNDSTRÜM, E., AND MEFFORD, I. (1985) Deficits in behavioral initiation and execution processes in monkeys with 1-methyl -4-phenyl -1,2,3,6 - tetrahydropyridine - induced parkinsonism. Neurosci. Lett. 59: 225-232
41. SCHULZER, M., LEE, C. S., MAK, E. K., VINGERHOETS, F. J. G., AND CALNE, D. B. (1994) A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 117: 509-516
42. STERN, Y. (1990) MPTP-induced Parkinsonism. Prog. Neurobiol. 34: 107-114
43. TAYLOR, J. R., ELSWORTH, J. D., ROTH, R. H., SLADEK, J. R., AND REDMOND, D. E. (1994) Behavioral effects of MPTP administration in the Vervet monkey, a primate model of Parkinson's disease. In: Toxin-induced models of neurological disorders, WOODRUFF ML, and NONNEMAN A (Eds) pp 139-151, Plenum Press, New York.
44. TETRUD, J. W., AND LANGSTON, J. W. (1992) Tremor in MPTP-induced parkinsonism. Neurology 42: 407-410
45. UHL, G. R., HEDREEN, J. C., AND PRICE, D. L. (1985) Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35: 1215-1218
46. VINGERHOETS, F. J. G., SNOW, B. J., LEE, C. S., SCHULZER, M., MAK, E., AND CALNE, D. B. (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 36: 759-764